From farm to fund: A practical guide to Canadian agritech M&A

Why Canadian agritech M&A is not a software deal

This is a consequential moment for Canadian agritech. Recent volatility in fertilizer and energy inputs, combined with ongoing supply chain disruption and geopolitical pressure on global agricultural systems has underscored how exposed farm economics remain to factors that do not align neatly with software-style scalability. At the same time, significant pools of capital have turned toward the sector in search of growth, often applying valuation frameworks developed in other industries.

A recurring pattern in Canadian agritech transactions is that the parties often price, structure, and integrate the deal as if it were a software or industrial acquisition. Agritech ventures run on growing seasons, regulatory registration cycles, grower trust, and a narrow universe of likely strategic buyers. The companies building them are a blend of biology, hardware, software, and commercial agronomy, and the mix sits differently in each sub-sector. The central mistake in Canadian agritech M&A is not misunderstanding technology, it is misapplying software deal logic to businesses whose value is governed by biology, regulation, and physical supply chains.

The interaction of these dynamics is increasingly visible in transaction outcomes. Agritech businesses are evaluated not only for their growth potential, but also for their ability to reduce input dependency, support more consistent yields, and integrate into existing agricultural systems. In that context, applying a conventional software M&A framework to agritech transactions can lead to misaligned expectations around value, diligence, and integration. This article is about how to avoid those outcomes.

The Canadian agritech landscape in brief

Canadian agriculture generated $149.2 billion in 2024 and accounts for roughly one in nine Canadian jobs (Agriculture and Agri-Food Canada, 2024–25 Departmental Results Report). The innovation layer above that base is supported by the federally funded Global Innovation Clusters, notably Protein Industries Canada, Scale AI, and Canada’s Ocean Supercluster, along with Bioenterprise Canada, Farm Credit Canada’s FCC Capital program, and the $3.5 billion Sustainable Canadian Agricultural Partnership.

Regional ecosystems differ meaningfully:

• The prairies host most of Canada’s crop-focused agritech activity, anchored by Saskatoon, Winnipeg, and Regina, and by the proximity of grain-handling and input-distribution infrastructure.
• Ontario and Quebec concentrate food-processing and ingredient manufacturing, with Quebec’s supply-managed dairy, poultry, and egg sectors and its cooperative structures (Sollio, Agropur, Saputo) shaping a distinctive institutional environment that out-of-province buyers should factor into any deal plan.
• Atlantic Canada’s aquaculture and seafood-processing intersect with the Ocean Supercluster.
• British Columbia contributes controlled-environment agriculture, horticulture, and wine-sector innovation.

A credible Canadian agritech transaction plan engages with the region in which the target operates, rather than assuming a pan-Canadian uniformity that does not exist. In practice, these regional distinctions translate directly into transaction complexity including regulatory regimes, cooperative structures, and local distribution dynamics that can materially affect both valuation and integration strategy, particularly for out-of-province or foreign buyers.

The capital gap and why it matters for deals

Capital is arriving in greater quantity than in any prior era:

• Farm Credit Canada committed $2 billion to direct investment under FCC Capital in May 2025 and, in February 2026, convened a coalition of more than twenty investment organizations prepared to deploy up to a further $5 billion into Canadian agriculture and food innovation by 2030.
• At the same time, RBC Thought Leadership’s February 2026 report, Seeding Scale, found that the sector represents a $13 billion investment opportunity, but remains materially undercapitalized, attracting roughly 4% of total growth capital invested in Canada over the past five years.

This disconnect between capital availability and deployment is not just a market observation – it directly shapes transaction timing, with many vendors entering sale processes earlier than expected and with a narrower field of credible bidders than headline capital figures would suggest.

Recent deal activity illustrates the range of transaction types:

• In June 2024, Nutrien Ag Solutions completed the acquisition of Suncor Energy’s AgroScience biocontrol assets, a portfolio of patented and patent-pending technologies still years away from commercial revenue (EPA submissions anticipated by 2026).
• Louis Dreyfus commissioned a 75,000-tonne pea protein facility in Yorkton in 2025 and Roquette began doubling capacity at its Portage la Prairie plant in 2024 – large foreign multinationals investing in Canadian alt-protein processing rather than buying Canadian branded businesses outright.
• AGT Food and Ingredients partnered with Wamame Foods in April 2024 on plant-based meat alternatives.
• A Manitoba-founded digital agronomy company, Farmers Edge, which went public on the Toronto Stock Exchange at $17 per share in March 2021, was taken private by majority shareholder Fairfax Financial Holdings in early 2024 at $0.35 per share – a roughly 98% decline that reflected, among other things, public-market investors applying SaaS-style adoption-curve and unit-economics assumptions to a business operating on agricultural rather than software dynamics.

Taken together, these transactions reinforce a consistent pattern in Canadian agritech M&A: strategic buyers dominate, partnerships often precede acquisitions, and valuation outcomes frequently diverge from software-sector expectations where biological, regulatory, or infrastructure constraints are not fully priced in.

Lesson: For most Canadian agritech ventures, an IPO is not a realistic path to liquidity, it is a strategic sale or a commercial partnership with an established agribusiness, a universe of perhaps a dozen serious domestic and multinational buyers. Build toward that reality from the seed round onward and select advisors and investors who know who those buyers actually are.

The capital gap and why it shapes exit behaviour

The most financially material issue for many Canadian agritech founders is not sitting in a purchase agreement, it is sitting in the domestic growth-stage capital stack.

RBC’s Seeding Scale (PDF) report describes a structural gap between what Canadian agri-food companies need to scale and what domestic investors are equipped to provide. Companies raising beyond early venture rounds frequently find that domestic funds cannot write cheques of the size required to build a processing plant, fund a multi-jurisdictional regulatory programme, or finance a meaningful commercial launch.

The report characterises a recurring “$15 million cliff” where growth financing becomes hard to find.

When growth capital is scarce, exits happen earlier and on worse terms than they otherwise would. Founders facing the choice between another cash-constrained fundraise and an acceptable strategic offer tend to take the strategic offer. Foreign strategic investors who provide the capital to bridge the gap often end up as the natural buyer a year or two later. Companies that try to wait out the gap sometimes reach the public markets before they are ready, with Farmers Edge’s 2021 IPO and 2024 take-private serving as the most visible recent cautionary tale in the sector.

For buyers, the same dynamic is an opportunity: well-built Canadian agritech targets are often available at valuations that reflect the vendor’s capital constraint more than the technology’s commercial potential. For vendors, the dynamic is a warning: planning an exit pathway and cultivating multiple serious buyers well before the cash runway forces a decision materially improves outcomes.

Lesson: The capital gap is not just a fundraising problem – it is a deal-timing problem. Founders who assume they will simply raise another round when the time comes often find themselves transacting on compressed timelines with a single serious buyer. Start exit planning eighteen to twenty-four months before you think you need to.

Different agritech sub-sectors, different M&A rules

Agritech is not one market. The following sub-sectors play by different rules, and vendors and buyers should situate the target precisely before anything else.

Biologicals and biocontrol deals

Biologicals and biocontrol deals typically involve large seed and crop-protection incumbents as the most likely buyers, with multi-year regulatory registration pathways through the Pest Management Regulatory Agency (PMRA) and equivalent foreign authorities.

For instance, the Nutrien / Suncor AgroScience transaction is illustrative of how strategic agritech buyers price these assets differently than a software buyer would: Nutrien took on a portfolio whose lead product launch was still anticipated for 2025 and whose US regulatory submissions were not expected until 2026, accepting a multi-year wait between closing and meaningful revenue in exchange for proprietary technology that fits its existing distribution platform. In biologicals, the regulatory calendar dictates the transaction calendar.

Digital agronomy deals

Digital agronomy deals look like software deals on the surface, but face durability-of-adoption questions that pure-software buyers tend to underestimate:

• Grower adoption is slower and less sticky than enterprise SaaS adoption.
• Return on investment is often weather-dependent.
• The data asset that looks like a defensible moat may be subject to grower consent terms that do not survive a change of control.

Farmers Edge illustrated the sector’s public-market fragility; private-market buyers should apply agritech-specific rather than software-industry benchmarks.

Alternative protein deals

Alternative protein deals in Canada have trended toward capacity investment (Roquette’s Portage la Prairie expansion, Louis Dreyfus’s Yorkton commissioning) and ingredient-platform partnerships (AGT / Wamame) rather than acquisitions at the brand or finished-goods level. For vendors in this sub-sector, the likely near-term pathway is often a commercial partnership or a joint venture that ripens into an acquisition later rather than an immediate sale.

Farm automation and robotics deals

Farm automation and robotics deals raise a hybrid of hardware, software, and service-model considerations: capital intensity, service-network dependencies, and durability of the hardware itself in working-farm conditions are all priced differently than in pure-software deals.

Gene-editing ventures

Gene-editing ventures face an additional layer of IP-licence complexity, typically involving licences from one or more of the foundational CRISPR licensors, and regulatory regimes whose treatment of gene-edited products varies significantly across jurisdictions.

Lesson: What is standard in one agritech sub-sector can be unusual in another. Advisors, diligence scope, and comparable-deal benchmarks should all be selected to match the specific sub-sector, not agritech as a generic category.

Strategic or financial buyer?

Among the most consequential questions in an early deal plan is whether the likely buyer is either:

• a strategic buyer (an incumbent agribusiness integrating the target into its platform); or
• a financial buyer (typically a private equity or growth equity fund holding the target as a standalone platform).

The two paths involve materially different commercial expectations, deal structures, and post-closing dynamics.

Strategic buyers price on fit with their existing platform, which can support premium valuations for well-matched assets but can leave less-well-matched targets undervalued. Structures typically contemplate full acquisition, limited founder rollover, and integration that often winds down the standalone brand over time. The Nutrien / Suncor AgroScience acquisition is a clean example of this pattern.

Financial buyers typically preserve the target as a standalone platform, reinvest in growth, and plan toward an onward sale within a defined hold period. Founder and management rollover into post-closing equity is common, as is a new management incentive plan. Where a financial buyer is a controlling shareholder taking a listed agritech company private, as in Farmers Edge / Fairfax, the process adds layers of independent-committee governance, fairness opinions, and minority-shareholder protection mechanics under Multilateral Instrument 61-101.

When US buyers are involved: CFIUS and ICA

The US cross-border dimension matters here. Many of the most active strategic buyers of Canadian agritech are US or multinational incumbents, and a meaningful number of Canadian agritech startups adopt Delaware parent structures for investor-fit reasons, which affects the mechanics of any eventual exit. Where a US buyer is involved, The Committee on Foreign Investment in the United States (CFIUS) review in the United States and Investment Canada Act (ICA) review in Canada may both apply, and their timelines do not always align. Deal schedules and closing conditions should account for both regimes from the outset.

Lesson: A target whose natural buyer is a global seed company should be packaged, priced, and negotiated very differently from one whose natural buyer is a growth equity fund. Founders who maintain optionality between the two as long as possible almost always realize better terms than those who commit to a lane too early.

Intellectual property: where the value sits and what breaks deals

Intellectual property (IP) sits at the centre of most agritech transactions, but not always in the way a company’s pitch deck may suggest. Value is seldom captured by a single patent, dataset, or plant variety. Instead, both value and deal risk turn on what can be protected, who controls it, how it transfers on closing, and whether the overall IP framework can withstand growth and scale. In Canadian agritech transactions, a small number of recurring IP issues account for the majority of deal friction that leads to re‑pricing or, in some cases, failed transactions.

Where does the value actually live?

In agritech deals, value generally resides in the combination and alignment of multiple IP rights, rather than in any single right viewed in isolation. Most agritech businesses span biology, software, hardware, and regulatory regimes, and no one form of IP protection can fully protect such a business on its own. Enterprise value is typically created when different protections apply to various aspects of the same product or platform in a coordinated way.

Patents protect enabling technologies, plant breeders’ rights secure exclusivity over commercial varieties, and trade secrets and know-how cover processes or data that are impractical or unsuitable to patent. Software, data, and database rights, together with regulatory approvals and data packages, often play an equally important role in determining who can operate, improve, and scale the business over time.

Across agritech subsectors, buyers are ultimately assessing whether the IP framework allows the business to operate and grow without undue reliance on third parties. Where these rights are coherent and mutually reinforcing, value can accrue over time. Where the framework is fragmented or dependent on external consents, individual assets may not support the overall deal rationale.

What can break the deal?

Agritech transactions tend to encounter difficulty when the IP framework proves less durable or less integrated than originally assumed.

• Unclear ownership frequently arises where IP developed in universities, government programs, or collaborative research arrangements remains subject to residual rights.
• Licence dependency presents another common challenge, particularly where core technology is licensed rather than owned, subject to field-of-use restrictions, or exposed to termination or consent requirements on a change of control.

In digital agritech transactions, uncertainty around ownership and permitted use of data, trained models, and derived analytics can materially affect valuation assumptions. Patents, while not always central to the value narrative, may also give rise to risk where infringement exposure, narrow claim scope, or geographic limitations are identified.

These issues often surface later in the diligence process and can lead to re-pricing, additional structural protection, or extended negotiations.

What tends to get missed?

Even well‑executed diligence can overlook issues that matter because agritech value rarely sits in discrete, standalone assets.

• Data rights are a common area of exposure, as many agritech businesses rely on extensive agronomic and machine‑generated datasets governed by grower or partner agreements that were not drafted with ownership transfer, reuse, or ongoing model training in mind.
• Patent risk is also frequently underestimated, with portfolios assumed to provide broader protection than their claim scope supports, freedom‑to‑operate concerns muted by nominal ownership, and limited geographic coverage constraining scalability and valuation.
• Trade secrets are often treated as valuable without confirming that secrecy has been actively maintained through consistent confidentiality and assignment practices.
• Collaboration agreements may further affect long‑term value through improvement rights, licence‑backs, or shared ownership structures that become material as the business grows.
• Regulatory control is likewise sometimes assessed separately from IP ownership, increasing the risk that commercially important assets cannot be fully exploited post‑closing.

Lesson: For buyers, an Agritech IP diligence should be treated as an assessment of an integrated operating framework, not a checklist of assets. In practice, many of the most consequential risks (chain-of-title gaps, licence termination triggers, limited geographic coverage, and freedom-to-operate exposures) are embedded in underlying agreements that appear complete at first glance. Effective diligence requires review of the underlying documentation, not just summary schedules, and early involvement of advisors with both transactional and patent agent experience to test whether the IP framework supports the deal rather than undermines it post-closing.

Transaction stages: what to watch for

In agritech transactions, timing, diligence scope, and deal mechanics are shaped less by conventional deal process and more by biological cycles, regulatory calendars, and the practical realities of farm operations. Each stage of the transaction should be calibrated accordingly.

1.    Early planning and term sheet

Vendors should take stock of the full asset base including the technology, data, regulatory permits, grower relationships, founder credibility, and identify which elements transfer cleanly and which depend on specific people.

Unlike software transactions, where assets are typically transferable at closing, a meaningful portion of agritech value may be season-bound or validation-dependent, with data, performance, and customer relationships tied to specific growing cycles. Protein Industries Canada’s funded portfolio alone has reported 546 IP assets generated through cluster projects (Protein Industries Canada, Annual Report 2024–25), a reminder that documented know-how is usually a large part of what buyers pay for.

Buyers should calibrate integration-timeline expectations to agricultural rather than software reality: validation across Canadian growing conditions typically requires multiple growing seasons, meaning that full integration and value realization may lag behind closing by one to three crop cycles.

Earnouts, holdbacks, and escrow arrangements remain common price-bridging tools, but are often more difficult to calibrate than in software transactions.

Performance metrics tied to revenue or adoption may fluctuate based on weather, input costs, or regional growing conditions rather than underlying product quality, increasing the risk of misalignment between vendors and buyers.

The SRS Acquiom 2025 M&A Deal Terms Study, which analysed more than 2,200 private-target acquisitions closed between 2019 and 2024, found earnouts in roughly one in five private-target deals outside life sciences.

2.    Diligence and the purchase agreement

Agritech diligence reaches further than a vendor may expect. Diligence timelines are frequently longer and less predictable than in software deals, as key questions particularly around product efficacy and adoption may depend on multi-season field data that cannot be quickly replicated or verified.

Expect probing of field-trial data reliability, regulatory status of products under Canadian Food Inspection Agency (CFIA) or Pest Management Regulatory Agency (PMRA) review, plant breeders’ rights and patent scope, grower-data provenance and consent, and dependencies on specific grower-advisors or demonstration-farm partners.

Where the business has made any environmental or sustainability claims to growers, consumers, or downstream buyers, expect those claims to be tested as well. The Competition Act amendments enacted by Bill C-59 in 2024 introduced a reverse onus under which businesses must substantiate environmental claims on an adequate and proper basis, and the diligence stakes on this point have risen materially.

For Purchasers, this creates a diligence burden that goes beyond traditional regulatory compliance and into substantiation of performance claims made in marketing, grant applications, and grower-facing materials. Representations and warranties typically extend to regulatory approvals, IP ownership and validity (with appropriate knowledge qualifiers), compliance with producer data consents, and the accuracy of any environmental or sustainability claims.

In many agritech businesses, a material portion of value is closely tied to founder credibility within the grower community, which does not transfer automatically with the equity.

• Diligence should assess the degree to which adoption, data generation, or key commercial relationships are dependent on the founder’s personal involvement.
• Transaction structures, particularly retention, rollover, and earnout structures, should be thoughtfully calibrated to preserve this goodwill for at least one or two growing cycles.
• At the same time, non-competition and non-solicitation provisions must be carefully drafted to avoid unduly restricting founders who remain active farmers from operating their own farm or engaging in customary producer-community activities.

Purchase agreement drafting should also account for operational inflexibility during critical periods: interim covenants that are standard in other sectors (e.g., restrictions on entering contracts or altering operations) may need to be relaxed or specifically tailored to avoid disrupting planting, spraying, or harvest activities. Closing conditions typically include regulatory approvals, consents from key commercial partners, and where applicable Competition Act or Investment Canada Act clearances.

Where a US buyer is involved, CFIUS review timing should be factored in alongside the ICA review timing. Deal timing in agritech is often dictated as much by the agricultural calendar as by commercial readiness. Launching a sale process immediately before or during planting or harvest can limit management availability, delay diligence responses, and reduce buyer engagement.

Five things to remember

If we had to distil the lessons of the past several years of Canadian agritech transactions into a short list, it would be this:

1. Plan for a strategic sale from the seed round. The buyer universe for a Canadian agritech venture is small and identifiable. Building the company in a way that makes sense to two or three likely buyers yields better outcomes than building toward an IPO that rarely materializes.
2. The capital gap is a deal-timing problem. Canadian agritech companies that need to raise beyond $15 million frequently cannot do so and often transact from a position of cash-constrained weakness. Start exit planning eighteen to twenty-four months before the runway forces a decision, not after.
3. Sub-sector beats sector. Biologicals, digital agronomy, alt-protein, farm automation, and gene editing each play by different rules. Advisors who treat them interchangeably will misprice the deal and miss the diligence items that matter most.
4. IP problems are cheap to prevent and expensive to find late. Chain-of-title gaps, licence-in exposure, freedom-to-operate risk, and data-consent weaknesses almost always exist before the deal process – but they cost real dollars when they surface thirty days before signing. Scope diligence to the actual documents, not just the summary schedules.
5. The founder is often part of the asset. Grower-community credibility does not transfer automatically with the equity. Retention, rollover, and non-compete arrangements should reflect that reality – and should not inadvertently block a founder-farmer from running their own farm.

Across each stage of the process, agritech M&A transactions are more successful when their structure, timing, and risk allocation reflect the realities of agricultural cycles, regulatory timelines, and field-level performance, rather than defaulting to conventional M&A assumptions.

Miller Thomson is participating in the upcoming Agritech Venture Forum, an event we view as critical to the Canadian and North American agribusiness ecosystem. To discuss any of the issues raised here, please reach out to any of the authors or another member of Miller Thomson’s Canadian Mergers & Acquisitions lawyers, Technology, Intellectual Property and Privacy lawyers, or Agribusiness and Food Production lawyers.